75.03
+3.11%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Corcept Therapeutics
From its filings with the US Securities and Exchange Commission
Corcept Therapeutics is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CORT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $761.4m and net income of $99.7m. At that date it held total assets of $836.7m and shareholders' equity of $647.8m.
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.
Cortisol plays a significant role in the body’s response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon awakening and decreasing during the day. Insufficient cortisol activity may lead to dehydration, hypotension, shock, fatigue and hypoglycemia. Excessive cortisol activity, known as hypercortisolism, may lead to hypertension, diabetes, impaired glucose tolerance, obesity, fatty liver disease, depressed mood, psychosis, wasting of the arms and legs, edema, fatigue, insomnia and other problems.
Cortisol reduces a patient’s immune response to oncogenesis, shields certain cancer cells from the apoptotic effects of chemotherapy and facilitates the growth of others. Pre-clinical and clinical data indicate that modulating cortisol activity may improve outcomes in patients with fatty liver disease and metabolic dysfunction-associated steatohepatitis (“MASH”), which are precursors of liver fibrosis and cirrhosis. Pre-clinical and clinical data also suggest that modulating cortisol activity may lead to treatments for patients with amyotrophic lateral sclerosis (“ALS”).
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Apr 2004
- Employees
- 730
- Website
- corcept.com ↗
- Head office
- 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. James WilsonIndependent Chairman of the Board, since 1999$1.5m
- Dr. Joseph BelanoffPresident, Chief Executive Officer, Co-Founder, Director, since 1999$9.9m
- Mr. Atabak MokariChief Financial Officer, Treasurer$3.9m
- Mr. Sean MaduckPresident - Corcept Endocrinology, since 2022$4.0m
- Mr. Joseph LyonChief Accounting and Technology Officer
- Dr. Hazel HuntChief Scientific Officer$3.1m
- Mr. William GuyerChief Development Officer$4.0m
- Mr. Gary RobbChief Business Officer, Secretary$4.1m
- Mr. Gregg AltonIndependent Director$601,410
- Mr. George BakerIndependent Director$582,410
- Dr. Gillian CannonIndependent Director$584,910
- Mr. David MahoneyIndependent Director$598,910
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 27
- Environment
- 4
- Social
- 19
- Governance
- 59
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Corcept Therapeutics Inc has several strengths that contribute to its success in the pharmaceutical industry:
Weaknesses
- Despite its strengths, Corcept Therapeutics Inc also faces certain weaknesses that pose challenges to its growth and competitiveness:
Opportunities
- Corcept Therapeutics Inc can explore various opportunities to further enhance its business and drive future growth:
Threats
- Corcept Therapeutics Inc faces certain threats that may impact its business operations and market position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.